A Practical Analysis Of GlaxoSmithKline plc’s Dividend

Is GlaxoSmithKline plc (LON: GSK) in good shape to deliver decent dividends?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The ability to calculate the reliability of dividends is absolutely crucial for investors, not only for evaluating the income generated from your portfolio, but also to avoid a share-price collapse from stocks where payouts are slashed.

There are a variety of ways to judge future dividends, and today I am looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) to see whether the firm looks a safe bet to produce dependable payouts.

Forward dividend cover

Forward dividend cover is one of the most simple ways to evaluate future payouts, as the ratio reveals how many times the projected dividend per share is covered by earnings per share. It can be calculated using the following formula:

Forward earnings per share ÷ forward dividend per share

GlaxoSmithKline is anticipated to provide a dividend of 74.5p per share in 2013, according to broker estimates, with earnings per share for this period forecast to come in at 116.2p. This means that dividend cover works out at 1.6 times prospective earnings, below the widely-regarded security threshold of 2 times.

Free cash flow

Free cash flow is essentially how much cash has been generated after all costs and can often differ from reported profits. Theoretically, a company generating shedloads of cash is in a better position to reward stakeholders with plump dividends. The figure can be calculated by the following calculation:

Operating profit + depreciation & amortisation – tax – capital expenditure – working capital increase

The pharma giant registered free cash flow of £2.05bn in 2012. This was down more than 50% from £4.14bn in the prior 12-month period, with a significant fall in operating profit — to £7.38bn from £7.81bn — weighing on cash flow. An increase in capex costs, allied to the phasing of tax payments, also caused the heavy deterioration.

Financial gearing

This ratio is used to gauge the level debt a company carries. Simply put, the higher the amount, the more difficult it may be to generate lucrative dividends for shareholders. It can be calculated using

the following calculation:

Short- and long-term debts + pension liabilities – cash & cash equivalents

___________________________________________________________ x 100

Shareholder funds

GlaxoSmithKline’s gearing readout came out at 192% in 2012, leaping from 72% in the previous year. This was primarily due to net debts advancing to £14.04bn last year from £9bn in 2011, driven by ongoing legal action in the US and the purchase of its HGS division for £2bn. As well, cash and cash equivalents fell during the period, while shareholder funds also dipped in 2012.

Buybacks and other spare cash

Here I’m looking at the amount of cash recently spent on share buybacks, repayments of debt and other activities that suggest the company may in future have more cash to spend on dividends.

GlaxoSmithKline is currently engaged in an active share repurchase programme, and has pencilled in buybacks worth between £1bn and £2bn for the current year. This is down from £2.5bn purchased in 2012 but still represents a meaty sum.

Typical of all pharmaceutical operators, GlaxoSmithKline devotes huge amounts of capital to R&D — as well as bubbly work on the acquisition front — to develop a fruitful product pipeline.

This is a theme hastened by the problem of major product expirations in recent times which has damaged revenue growth. Thus capex outlay should continue heading northwards. The company is aiming to introduce 15 key products across the globe over the next three years, in a bid to ‘grow a diversified global business’ and ‘deliver more products of value’.

The prescription for prize dividends

I believe that this devotion to innovation and expansion should deliver increasingly-appetising earnings growth, a situation which should undergird solid dividend expansion. The company boasts a stellar record of increasing full-year payouts even in times of earnings pressure, and I fully expect payments to roll relentlessly higher looking ahead.

And for the current year, the firm is ready to produce a dividend yield of 4.4% in 2013, if City estimates prove correct. This signals a very decent return compared with the FTSE 100 average of 3.3%.

The inside track to hot stocks growth

If you already hold shares in GlaxoSmithKline and are looking to significantly boost your investment returns elsewhere, check out this special Fool report, which outlines the steps you might wish to take in order to become a market millionaire.

Our “Ten Steps To Making A Million In The Market” report highlights how fast-growth small-caps and beaten-down bargains are all fertile candidates to produce ten-fold returns. Click here to enjoy this exclusive ‘wealth report’ — it’s 100% free and comes with no obligation.

> Royston does not own shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Middle-aged black male working at home desk
Investing Articles

Are these top-traded FTSE 100 shares the best to buy for 2024?

The market has disagreed with me pretty much all year on the best buys among FTSE 100 shares. But, are…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

My five favourite forms of passive income

I've been looking for ways to pump up my passive income, so I can retire richer. But which of these…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

What’s the FTSE 100’s best 10% dividend yield?

Depressed prices have thrown up some golden opportunities on the FTSE 100. Which of these 10%-yielding Footsie stocks should I…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

BP shares look dirt cheap

Are BP shares a brilliant bargain? The financials look excellent and it’s hard not to call them anything other than…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

My 12 fears for the stock market in 2024

After a terrific year for global stock markets in 2023, what can I look forward to in 2024? As a…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

2 income shares for bumper dividends in 2024

I own these two income shares for their outstanding ability to deliver billions of pounds of cash dividends each year…

Read more »

Investing Articles

Could the IAG share price hit £2.11 in 2024?

According to analysts, the IAG share price could be headed for £2.11. But Stephen Wright wonders whether the stock is…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

1 hot UK growth stock I’m buying right now

I've more than doubled my money on this UK growth stock. But with a 948% boost to earnings, I think…

Read more »